At a glance
- Originator Novartis
- Class Analgesics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 27 Aug 2003 Discontinued - Preclinical for Pain (PO)
- 13 Jun 2001 No-Development-Reported for Pain (PO)
- 24 Jun 1998 Preclinical development for Pain (PO)